CRISPR RNA Diagnostics for Cold-Chain-Free Hemorrhagic Fever Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for hemorrhagic fevers, particularly Lassa fever, face challenges such as genetic diversity of the LASV genome, rapid viral evolution, and logistical constraints in endemic regions, leading to low sensitivity and feasibility issues, especially in remote areas lacking laboratory facilities and cold chains.
Innovation Solution
A CRISPR-based diagnostic system utilizing effector proteins and guide molecules, combined with RNA-based masking constructs and nucleic acid amplification reagents, enables rapid and sensitive detection of hemorrhagic fever viruses without the need for a cold chain, using lyophilized reagents and glass fiber paper for point-of-care applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular diagnostic methods are used for Lassa fever detection, then detection sensitivity can be improved, but the requirement for laboratory facilities and cold chain increases
Solution Approach 1:
The patent extracts the essential diagnostic function from complex laboratory settings by developing a point-of-care test that can be performed without specialized equipment. The lateral flow assay format removes the need for laboratory facilities, while maintaining detection capability through immunochromatographic principles.
Solution Approach 2:
The patent employs disposable lateral flow test strips that eliminate the need for expensive, maintainable laboratory equipment. These single-use devices contain pre-loaded reagents and provide immediate results, making diagnostics accessible in resource-limited settings without cold chain requirements.
2Measurement precision
If diagnostic tools are designed for high sensitivity, then viral detection capability is improved, but feasibility in remote areas deteriorates
Solution Approach 1:
The lateral flow assay is designed to be self-contained and self-explanatory, requiring minimal training for operation. The test strip automatically performs the diagnostic function when the sample is applied, with results visible through color changes on the strip itself, enabling community health workers to conduct tests independently in remote areas.
Solution Approach 2:
The patent changes the operational parameters from laboratory-based molecular methods requiring controlled environments to a point-of-care immunochromatographic assay that operates at ambient conditions. This parameter change enables deployment in remote areas while maintaining detection capability through optimized antibody-antigen interactions on the lateral flow strip.
3Measurement precision
If existing molecular diagnostics are used, then detection accuracy can be maintained, but sensitivity to current LASV strains decreases
Solution Approach 1:
The patent employs a flexible diagnostic platform where the lateral flow assay can be rapidly reconfigured by changing the capture and detection antibodies. This dynamic design allows the test to be updated to recognize new LASV strains or variants, maintaining both detection accuracy and sensitivity to current strains through adaptable reagent selection.
Solution Approach 2:
The patent incorporates preliminary optimization of antibody selection and test strip formulation during development to ensure high sensitivity to current LASV strains. By pre-testing and selecting antibodies with optimal binding characteristics against circulating strains, the assay achieves both accurate detection and high sensitivity before deployment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides high sensitivity and specificity for detecting hemorrhagic fever viruses, including Lassa virus strains, with attomolar detection limits, and can differentiate between strains, overcoming the limitations of existing methods by being deployable in resource-limited settings.
Implementation Method 1
one or more CRISPR systems each comprising an effector molecule and one or more guide molecules that are specific to one or more target molecules of one or more hemorrhagic fever viruses
Implementation Method 2
an RNA-based masking construct that suppresses generation of a detectable positive signal
Data Source
AI summary
The embodiments disclosed herein utilize RNA targeting effectors to provide a robust CRISPR-based diagnostic for hemorrhagic fever virus applications. Embodiments disclosed herein can differentiate between hemorrhagic fever viruses that present with similar symptoms, as well as between strains of a hemorrhagic fever virus.